KRAS and familial pancreatic carcinoma: Approximately 30% of pancreatic cancer patients harbor druggable mutations; for example, KRAS, BRCA1 and 2, PALB2, ATM, HER2, MET, MLH1, MSH2, MSH6, PMS2, PI3CA, PTEN, CDKN2A, BRAF, and FGFR1 [2].